TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30280515

Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate (SH) ophthalmic solution
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.2% sodium hyaluronate (SH) ophthalmic solution
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate (SH) ophthalmic solution
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: All sodium hyaluronate solutions
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: All ophthalmic solutions
Number of subjects: 23
Study: 27748740

Group type: EXPERIMENTAL
Intervention: Arbaclofen
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 25901590

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation-based end-of-life care education
Number of subjects: 187

Group type: COMPARATOR
Intervention: Classroom-based end-of-life care education
Number of subjects: 187
Study: 23999423

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 236
Study: 21205435

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Mirtazapine and Venlafaxine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 23
Study: 19489802

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact for 25 to 120 minutes after birth, early suckling, or both
Number of subjects: 176

Group type: COMPARATOR
Intervention: Rooming-in after a 2-hour separation
Number of subjects: 176

Group type: COMPARATOR
Intervention: Swaddling of the infant
Number of subjects: 176
Study: 17998498

Group type: EXPERIMENTAL
Intervention: Intervention group (PIM completion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no PIM completion)
Number of subjects: 40
Study: 14994114

Group type: EXPERIMENTAL
Intervention: 0.2 percent isosorbide dinitrate ointment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 54
Study: 12074178

Group type: EXPERIMENTAL
Intervention: Low-NaFeEDTA group (consuming fortified soy sauce, providing 5 mg Fe/day)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: High-NaFeEDTA group (consuming fortified soy sauce, providing 20 mg Fe/day)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group (consuming non-fortified soy sauce)
Number of subjects: 304
Study: 9844789

Group type: EXPERIMENTAL
Intervention: Dihydrexidine (full D1 receptor agonist), single intravenous doses ranging from 2 mg to a maximum of 70 mg infused over 15 or 120 minutes
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dihydrexidine (full D1 receptor agonist)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 4
Study: 7865640

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for 5 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dosing after food
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2556456

Group type: EXPERIMENTAL
Intervention: Enalapril, 80 mg/day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 4331769

Group type: EXPERIMENTAL
Intervention: Kethoxal 2.5% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study: 31542942

Group type: EXPERIMENTAL
Intervention: Once-weekly exenatide (EQW)
Number of subjects: 14752
Study: 28422269

Group type: EXPERIMENTAL
Intervention: Wake therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 64
Study: 25297637

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐SA (1.5 μg kg(‐1) s.c.)
Number of subjects: 38

Group type: COMPARATOR
Intervention: peginterferon‐α‐2a (180 μg s.c.)
Number of subjects: 38
Study: 23154126

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PLEX)
Number of subjects: 62
Study: 21610124

Group type: EXPERIMENTAL
Intervention: Oral insulin treatment
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 19289135

Group type: EXPERIMENTAL
Intervention: Treadmill-walking exercise (twice weekly for 8 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-exercise control
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Treadmill-walking exercise
Number of subjects: 16
Study: 16464138

Group type: EXPERIMENTAL
Intervention: Advanced Illness Coordinated Care Program (AICCP)
Number of subjects: 275
Study: 15482045

Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Prolonged exposure plus cognitive restructuring
Number of subjects: 54
Study: 11198829

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218

Group type: COMPARATOR
Intervention: Naproxen sodium 550 mg
Number of subjects: 218
Study: 9489517

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (GTN)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7999813

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 23
Study: 3075559

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30279194

Group type: EXPERIMENTAL
Intervention: EGFR blockade
Number of subjects: 0
Study: 28561192

Group type: EXPERIMENTAL
Intervention: No cardiovascular medication
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Peripherally acting medication
Number of subjects: 18

Group type: COMPARATOR
Intervention: Centrally acting medication
Number of subjects: 18
Study: 25565587

Group type: EXPERIMENTAL
Intervention: Standard care along with receipt of twice‐daily supportive SMS text messages during the second and third week of the study
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 68
Study: 23866706

Group type: EXPERIMENTAL
Intervention: Modified orbital decompression in group CON (compressive optic neuropathy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified orbital decompression in group CON
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified orbital decompression in group MP (marked proptosis)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified orbital decompression in group MP
Number of subjects: 40
Study: 21179033

Group type: EXPERIMENTAL
Intervention: Immediate large loop excision (LLETZ)
Number of subjects: 989

Group type: COMPARATOR
Intervention: Two to four targeted punch biopsies with recall for LLETZ if necessary
Number of subjects: 989
Study: 18855992

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ulinastatin (2500 U/min)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ulinastatin (5000 U/min)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 175
Study: 17310422

Group type: EXPERIMENTAL
Intervention: Teleretinal imaging group, n = 223
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control group, n = 225
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Teleretinal imaging
Number of subjects: 448
Study: 12729114

Group type: EXPERIMENTAL
Intervention: Internal fixation (IF) with two cannulated screws
Number of subjects: 102

Group type: COMPARATOR
Intervention: Total hip replacement (THR)
Number of subjects: 102
Study: 10597556

Group type: EXPERIMENTAL
Intervention: Desflurane in oxygen/air
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desflurane in oxygen/nitrous oxide
Number of subjects: 60
Study: 8921775

Group type: COMPARATOR
Intervention: High supplementary vitamin E intake (>= 100 IU/day) in the placebo group
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo group with low vitamin E intake
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Vitamin E within the drug group
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Vitamin C within the drug group
Number of subjects: 146

Group type: COMPARATOR
Intervention: Vitamin C within the placebo group
Number of subjects: 146
Study: 1715740

Group type: EXPERIMENTAL
Intervention: FK506 with low-dose steroids
Number of subjects: 110

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 110
Study: 385873

Group type: EXPERIMENTAL
Intervention: 1,200 mg oxaprozin given as a single daily dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3,900 mg ASA given in 4 equally divided doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: oxaprozin
Number of subjects: 0
Study: 31630683

Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with Bifidobacterium breve CECT7263
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard powdered infant formula (Control group)
Number of subjects: 236
Study: 29086988

Group type: EXPERIMENTAL
Intervention: DDD‐40 RV‐only pacing
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: DDD‐40 BIV pacing
Number of subjects: 9

Group type: COMPARATOR
Intervention: VVI‐40 back up pacing
Number of subjects: 9
Study: 26192249

Group type: EXPERIMENTAL
Intervention: Child-parent psychotherapy (CPP)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 159
Study: 24381967

Group type: EXPERIMENTAL
Intervention: 2000 IU/d of alpha tocopherol
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: 20 mg/d of memantine
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Combination of alpha tocopherol and memantine
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 22073938

Group type: EXPERIMENTAL
Intervention: Air-particle abrasion with 50 μm Al(2)O(3) (0.4-0.7 MPa) during 20 s
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mechanical retentions with carbide burrs
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thermocycling (500 cycles, 5-55°C) applied to both groups
Number of subjects: 48

Group type: COMPARATOR
Intervention: Thermocycling not applied
Number of subjects: 48
Study: 20024737

Group type: EXPERIMENTAL
Intervention: Discussion of oral health with HIV primary care providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Five or more primary care visits in the past year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Illicit drug use among men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Each additional health topic discussed
Number of subjects: 0
Study: 17166765

Group type: EXPERIMENTAL
Intervention: iTBS(SH)
Number of subjects: 6

Group type: COMPARATOR
Intervention: cTBS(IH)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study: 16400234

Group type: EXPERIMENTAL
Intervention: Active treatment with aluminium hydroxide adsorbed house dust mite allergoid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11985408

Group type: EXPERIMENTAL
Intervention: Low-saturated fat, low-cholesterol diet (intervention group)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Unrestricted diet (control group)
Number of subjects: 307
Study: 9790206

Group type: EXPERIMENTAL
Intervention: Doppler-guided subclavian vein catheterization using the Smart Needle
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard subclavian vein catheterization
Number of subjects: 240
Study: 7714640

Group type: EXPERIMENTAL
Intervention: Community-based nursing and homemaker services; individualized support and education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homemaker assistance during the first 8 weeks after discharge
Number of subjects: 0
Study: 3067179

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multiple injections (MI)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 45
Study: 29688838

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment applied directly on the eyelids, with three treatments at 4-week intervals.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham IPL treatment (control group).
Number of subjects: 44
Study: 28556458

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention (provision of hardware: bin for solid waste, 4 l flushing bucket, 70 l water reservoir; behaviour change communication: compound meetings, interpersonal household sessions, signs depicting rules for toilet use)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Number of subjects: 1226
Study: 26542698

Group type: EXPERIMENTAL
Intervention: CTP-derived parameters (ischemic-core volume, percentage ischemic core, penumbra volume)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: CTP-derived parameters (percentage ischemic core)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: CTP-derived parameters (penumbra volume)
Number of subjects: 175
Study: 22926459

Group type: EXPERIMENTAL
Intervention: Specific timely appointments for triage (STAT)
Number of subjects: 971

Group type: COMPARATOR
Intervention: Control site (triaged waitlist)
Number of subjects: 971
Study: 20865582

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at 0.5 mcg/kg/hour during operation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (9% NaCl at the same rate and volume)
Number of subjects: 40
Study: 19045962

Group type: EXPERIMENTAL
Intervention: Problem-solving treatment for primary care (PST-PC)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study: 20139785

Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 85% of VO(2peak)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intermittent exercise at 70% of VO(2peak)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 85% of VO(2peak) (trained subjects only)
Number of subjects: 18

Group type: COMPARATOR
Intervention: All exercise trials
Number of subjects: 18
Study: 16286102

Group type: EXPERIMENTAL
Intervention: Pathway Access Sheath (PAS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: High-pressure balloon catheter (control)
Number of subjects: 21
Study: 11483173

Group type: EXPERIMENTAL
Intervention: College students faced with hypothetical discount cards for supermarkets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older adults faced with hypothetical discount cards for supermarkets
Number of subjects: 0
Study: 9593008

Group type: EXPERIMENTAL
Intervention: ALVAC-gp160/rgp120
Number of subjects: 0

Group type: COMPARATOR
Intervention: ALVAC-gp160
Number of subjects: 0

Group type: COMPARATOR
Intervention: rgp120
Number of subjects: 0
Study: 8162979

Group type: EXPERIMENTAL
Intervention: Home rehabilitation programme for 12 weeks, including physiotherapy and supervision by a nurse and general practitioner
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Home rehabilitation programme for 12 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (15 patients, no rehabilitation)
Number of subjects: 43
Study: 3074776

Group type: EXPERIMENTAL
Intervention: Redivac suction drain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous corrugated drains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative pyrexia (three degrees examined)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration of amnion rupture and number of vaginal examinations
Number of subjects: 0
Study: 31796304

Group type: EXPERIMENTAL
Intervention: Remifentanil 1μg.kg‐1 bolus + 0.15μg.kg‐1.min‐1 infusion (stopped after skin incision)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Remifentanil 1μg.kg‐1 bolus
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no remifentanil until delivery)
Number of subjects: 51
Study: 29932460

Group type: EXPERIMENTAL
Intervention: Year-long vegetable gardening intervention
Number of subjects: 0
Study: 26818407

Group type: EXPERIMENTAL
Intervention: TAU plus brief CBT-based intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: TAU (control group)
Number of subjects: 50
Study: 23760975

Group type: EXPERIMENTAL
Intervention: Anti‐Stigma Project workshop
Number of subjects: 258
Study: 22264146

Group type: EXPERIMENTAL
Intervention: Systematic instruction
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional instruction (trial-and-error learning)
Number of subjects: 29
Study: 18722608

Group type: EXPERIMENTAL
Intervention: Physiologic oxygen concentration (6% CO(2) + 5% O(2) + 89% N(2)) throughout culture period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atmospheric condition (6% CO(2) in air) until day 3, then physiologic environment
Number of subjects: 0
Study: 19087756

Group type: EXPERIMENTAL
Intervention: Massage therapy (10 sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control sessions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Massage therapy and Control
Number of subjects: 100
Study: 15631314

Group type: EXPERIMENTAL
Intervention: Duodenum preserving pancreatic head resection (Beger technique and its variations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical techniques (Whipple procedure)
Number of subjects: 0
Study: 11762564

Group type: EXPERIMENTAL
Intervention: Midazolam oral syrup administration
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Midazolam intravenous administration
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Midazolam bioavailability
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Initial oral dose of midazolam
Number of subjects: 87
Study: 9567248

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole/trimethoprim plus norfloxacin (ST + NFLX)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sulfamethoxazole/trimethoprim alone (ST)
Number of subjects: 75
Study: 8149521

Group type: EXPERIMENTAL
Intervention: Hirudin (0.05, 0.10, 0.20, or 0.30 mg.kg‐1.h‐1 infusion)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 166

Group type: COMPARATOR
Intervention: Heparin (target aPTT of 65 to 90 or 90 to 110 seconds)
Number of subjects: 166
Study: 3144979

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 109

Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 109
Study: 29475875

Group type: EXPERIMENTAL
Intervention: Ultra-conservative ICD programming strategy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard ICD programming by treating physician
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CRT ON
Number of subjects: 83

Group type: COMPARATOR
Intervention: CRT OFF
Number of subjects: 83
Study: 26041582

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 53
Study: 25727080

Group type: EXPERIMENTAL
Intervention: Home-based walking program
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 86
Study: 23446823

Group type: COMPARATOR
Intervention: Cefazolin alone (control arm)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Vancomycin and cefazolin (experimental arm)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: MRSA carriers
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Noncarriers
Number of subjects: 130
Study: 21035063

Group type: EXPERIMENTAL
Intervention: Atropine treatment
Number of subjects: 233

Group type: COMPARATOR
Intervention: Patching treatment
Number of subjects: 233
Study: 18218314

Group type: EXPERIMENTAL
Intervention: Nocturnal home hemodialysis (NHD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional hemodialysis (CHD)
Number of subjects: 32
Study: 16343769

Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NFT) in the Experimental (EXP) group (15 children)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No neurofeedback training in the Control (CON) group (5 children)
Number of subjects: 20
Study: 12180720

Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg once daily
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily
Number of subjects: 816

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 816
Study: 10343582

Group type: EXPERIMENTAL
Intervention: Neonatal repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3 month repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (neonatal and 3 month repair)
Number of subjects: 0
Study: 8942345

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 2 mg h‐1 (n = 12)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 1 mg h‐1 (n = 12)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Saline (n = 11)
Number of subjects: 47
Study: 1959410

Group type: EXPERIMENTAL
Intervention: CPAP 5 for 1 hour
Number of subjects: 106

Group type: COMPARATOR
Intervention: T-piece/ZEEP for 1 hour
Number of subjects: 106
Study: 7261637

Group type: EXPERIMENTAL
Intervention: Screening and intervention in high risk samples (HRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (LRS) that did not enter the trial
Number of subjects: 0
Study: 30611294

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-frequency electroacupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-frequency electroacupuncture
Number of subjects: 0
Study: 28326321

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided deep cervical plexus block
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fluoroscopy-guided deep cervical plexus block
Number of subjects: 56
Study: 25356799

Group type: EXPERIMENTAL
Intervention: 12-week home-based walking intervention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Nutrition education module (control)
Number of subjects: 69
Study: 25222305

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r)-based ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: nevirapine (NVP)-based ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: NVP-based ART
Number of subjects: 0